Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma

Multiple Myeloma (MM)

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium

Blood Cancer J

Varga C, Robinson M, Davis JA, Hashmi H, Martin TG, Kumar A, Sborov DW, Wagner CB, Hansen DK, Castaneda Puglianini O, Shune L, Bhurtel E, Afrough A, Anderson LD Jr, Dhakal B, Herr MM, Richard S, Lieberman-Cribbin A, Sherbenou D, Forsberg PA, Purvey S, Khouri J, Lin Y, Sidana S, Patel KK, Kocoglu M, Midha S, Ferreri CJ

doi: 10.1038/s41408-026-01469-z

Multiple Myeloma (MM)

B-cell maturation antigen-targeted CAR T cell as a salvage therapy for progressive multiple myeloma after anti-G proteincoupled receptor, class C group 5 member D CAR T-cell therapy

Haematologica

Zhang X, Xia F, Qi K, Xia J, Zhou D, Sun Q, Zhang H, Wang X, Sang W, Li D, Yan Z, Chang AH, Cao J, Pan B

doi: 10.3324/haematol.2026.301282

Multiple Myeloma (MM)

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma

Bone Marrow Transplant

Rasche L, Krauth MT, Agis H, Renner C, Strassl I, Teipel R, Vučinić V, Weisel K, Willenbacher W, Raab MS

doi: 10.1038/s41409-026-02905-1

Multiple Myeloma (MM)

Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort

Leuk Lymphoma

Leitner T, Oelschläger L, Henriquez Mosquera F, Schaefers C, Leypoldt L, Weisel K, von Bubnoff N, Rückert M, Kimmich C, Ahmed H, Vorwerk J, Khandanpour C

doi: 10.1080/10428194.2026.2699285

Multiple Myeloma (MM)

Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study

Blood Cancer J

Hansen DK, Dima D, Mian H, Devos J, Brazauskas R, Oloyede T, Afrough A, Ahmed N, Anderson L, Banerjee R, Berdeja JG, Bidikian A, Dhakal B, Dias A, Efebera Y, Faisal MS, Gowda L, Hashmi H, Mirza AS, Mohan M, Narra R, Rosko AE, Schroeder M, Nishihori T, Landau H, Usmani S, Pasquini MC, Akhtar OS, Sidana S, Patel KK

doi: 10.1038/s41408-026-01496-w

Multiple Myeloma (MM)

Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma

Blood Cancer J

Hashmi H, Sebastian T, Rajeeve S, Farzana T, Firestone RS, Jurgens EM, Miller KC, Maura F, Lesokhin AM, Tan CR, Shah GL, Korde N, Landau HJ, Merz M, Scordo M, Hassoun H, Maclachlan KH, Shah UA, Hultcrantz ML, Derkach A, Nemirovsky D, Giralt S, Mailankody S, Usmani SZ

doi: 10.1038/s41408-026-01494-y

Lymphoma

Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting

Br J Haematol

Villeneuve PJA, Mozessohn L, Somé NH, Mercer RE, Masucci L, Kouroukis T, Bredeson C, Aktar S, Guan Q, Prica A, Chen CI, Rodin D, Cheung M, Chaudhry M, Gavura S, McKay C, Wong WWL, Chan KKW

doi: 10.1111/bjh.70632

Multiple Myeloma (MM)

Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study

Clin Cancer Res

Suvannasankha A, Li M, Omofuma O, Hampp C, Phelan M, Breskin A, Shao P, Roccia T, Mukherjee N, Shrestha A, Lee D, Glass J, Kroog GS, Rodriguez Lorenc K

doi: 10.1158/1078-0432.CCR-25-4068

LeukemiaLymphomaCOVID-19

Efficacy and safety of radiotherapy as a bridging strategy to CD19-targeted CAR-T therapy: systematic review and meta-analysis

Leuk Lymphoma

Yu Y, Xiang Z, Hou X, Hu K, Zhang F

doi: 10.1080/10428194.2025.2572420

Related content

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium

B-cell maturation antigen-targeted CAR T cell as a salvage therapy for progressive multiple myeloma after anti-G proteincoupled receptor, class C group 5 member D CAR T-cell therapy

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma

Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort

Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study

Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma

Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting

Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study

Efficacy and safety of radiotherapy as a bridging strategy to CD19-targeted CAR-T therapy: systematic review and meta-analysis